$BDSX
BIODESIX INC

2024 Q4 Form 10-Q Financial Statement

#000095017024119792 Filed on November 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $18.15M
YoY Change 34.54%
Cost Of Revenue $4.179M
YoY Change 29.38%
Gross Profit $13.97M
YoY Change 36.18%
Gross Profit Margin 76.98%
Selling, General & Admin $20.02M
YoY Change 29.17%
% of Gross Profit 143.26%
Research & Development $2.547M
YoY Change 31.42%
% of Gross Profit 18.23%
Depreciation & Amortization $1.000M
YoY Change 233.33%
% of Gross Profit 7.16%
Operating Expenses $26.74M
YoY Change 29.42%
Operating Profit -$8.591M
YoY Change 19.79%
Interest Expense -$2.041M
YoY Change -185.54%
% of Operating Profit
Other Income/Expense, Net -$1.667M
YoY Change -55.86%
Pretax Income -$10.26M
YoY Change -6.32%
Income Tax
% Of Pretax Income
Net Earnings -$10.26M
YoY Change -6.31%
Net Earnings / Revenue -56.51%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.07
COMMON SHARES
Basic Shares Outstanding 145.5M 145.2M
Diluted Shares Outstanding 146.3M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.41M
YoY Change 58.62%
Cash & Equivalents $31.41M
Short-Term Investments
Other Short-Term Assets $4.575M
YoY Change 39.99%
Inventory
Prepaid Expenses
Receivables $8.036M
Other Receivables $0.00
Total Short-Term Assets $44.02M
YoY Change 52.38%
LONG-TERM ASSETS
Property, Plant & Equipment $28.68M
YoY Change 12.95%
Goodwill $15.03M
YoY Change 0.0%
Intangibles $6.438M
YoY Change -23.5%
Long-Term Investments
YoY Change
Other Assets $6.656M
YoY Change -4.44%
Total Long-Term Assets $58.73M
YoY Change 1.43%
TOTAL ASSETS
Total Short-Term Assets $44.02M
Total Long-Term Assets $58.73M
Total Assets $102.7M
YoY Change 18.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.537M
YoY Change -12.64%
Accrued Expenses $8.553M
YoY Change 23.14%
Deferred Revenue $700.0K
YoY Change 0.0%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $29.00K
YoY Change -71.0%
Total Short-Term Liabilities $12.96M
YoY Change -60.3%
LONG-TERM LIABILITIES
Long-Term Debt $36.11M
YoY Change 44.45%
Other Long-Term Liabilities $620.0K
YoY Change -23.93%
Total Long-Term Liabilities $61.92M
YoY Change 11.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.96M
Total Long-Term Liabilities $61.92M
Total Liabilities $74.89M
YoY Change -15.13%
SHAREHOLDERS EQUITY
Retained Earnings -$454.2M
YoY Change 10.68%
Common Stock $145.0K
YoY Change 64.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.86M
YoY Change
Total Liabilities & Shareholders Equity $102.7M
YoY Change 18.39%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.26M
YoY Change -6.31%
Depreciation, Depletion And Amortization $1.000M
YoY Change 233.33%
Cash From Operating Activities -$10.67M
YoY Change 177.89%
INVESTING ACTIVITIES
Capital Expenditures $286.0K
YoY Change -95.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$286.0K
YoY Change -95.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 144.0K
YoY Change -98.81%
NET CHANGE
Cash From Operating Activities -10.67M
Cash From Investing Activities -286.0K
Cash From Financing Activities 144.0K
Net Change In Cash -10.81M
YoY Change -544.98%
FREE CASH FLOW
Cash From Operating Activities -$10.67M
Capital Expenditures $286.0K
Free Cash Flow -$10.96M
YoY Change 12.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001439725
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsCurrent
CY2023Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39659
dei Entity Registrant Name
EntityRegistrantName
BIODESIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
dei Entity Address Address Line1
EntityAddressAddressLine1
919 West Dillon Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
Louisville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80027
dei City Area Code
CityAreaCode
303
dei Local Phone Number
LocalPhoneNumber
417-0500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BDSX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
145467295
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31406000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26284000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
246000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
65000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8036000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7679000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4575000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5720000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
44017000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
39683000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28683000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6438000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1918000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1745000
CY2024Q3 us-gaap Goodwill
Goodwill
15031000
CY2023Q4 us-gaap Goodwill
Goodwill
15031000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6656000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6859000
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
58726000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
59413000
CY2024Q3 us-gaap Assets
Assets
102743000
CY2023Q4 us-gaap Assets
Assets
99096000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2537000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2929000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8553000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
676000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
324000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
624000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
21857000
CY2024Q3 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
29000
CY2023Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
51000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
544000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
293000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12963000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33416000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
36112000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25191000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25163000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
620000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
712000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
61923000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
61100000
CY2024Q3 us-gaap Liabilities
Liabilities
74886000
CY2023Q4 us-gaap Liabilities
Liabilities
94516000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
145465941
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145465941
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96235883
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96235883
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
145000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
481958000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
424050000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-454246000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419566000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
27857000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
102743000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99096000
CY2024Q3 us-gaap Revenues
Revenues
18151000
CY2023Q3 us-gaap Revenues
Revenues
13491000
us-gaap Revenues
Revenues
50894000
us-gaap Revenues
Revenues
34419000
CY2024Q3 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
4179000
CY2023Q3 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3229000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
11231000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
9636000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2547000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1938000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7145000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8099000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20016000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15496000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60232000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51136000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
135000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
26742000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
20663000
us-gaap Operating Expenses
OperatingExpenses
78743000
us-gaap Operating Expenses
OperatingExpenses
68891000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8591000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7172000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27849000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34472000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2041000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2386000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
6506000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
7207000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-248000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1393000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1332000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
374000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1667000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3777000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6831000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8535000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10949000
us-gaap Net Income Loss
NetIncomeLoss
-34680000
us-gaap Net Income Loss
NetIncomeLoss
-43007000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146296000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146296000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79709000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79709000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123634000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123634000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78672000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78672000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
607000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2640000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-13614000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5502000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
33150000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18198000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1218000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10808000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
36260000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-15000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
343000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1515000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10258000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
27857000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-61000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2281000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4550000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2023Q2 bdsx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Optionsvested In Period Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
674000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1057000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13356000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6993000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15316000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
223000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
954000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10949000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1446000
us-gaap Profit Loss
ProfitLoss
-34680000
us-gaap Profit Loss
ProfitLoss
-43007000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4324000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2351000
bdsx Operating Lease Right Of Use Asset Accretion Amortization Expense
OperatingLeaseRightOfUseAssetAccretionAmortizationExpense
-266000
bdsx Operating Lease Right Of Use Asset Accretion Amortization Expense
OperatingLeaseRightOfUseAssetAccretionAmortizationExpense
1851000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-248000
us-gaap Share Based Compensation
ShareBasedCompensation
5373000
us-gaap Share Based Compensation
ShareBasedCompensation
4292000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1332000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
453000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
467000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
2167000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
3954000
us-gaap Inventory Write Down
InventoryWriteDown
20000
us-gaap Inventory Write Down
InventoryWriteDown
115000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
135000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
810000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1178000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-778000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1798000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-49000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
26000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-57000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-247000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
273000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-395000
bdsx Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
-23242000
bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
18323000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
682000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-237000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44553000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10587000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2391000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19935000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
165000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
126000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2556000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20061000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55625000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15316000
bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
624000
bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
643000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
90000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
7591000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
36000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
38000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
833000
bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
3685000
bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
61000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-276000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-127000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52231000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5122000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23247000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26371000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31493000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19927000
bdsx Issuance Of Perceptive Warrants
IssuanceOfPerceptiveWarrants
674000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
281000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
867000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
514000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
773000
us-gaap Interest Paid Net
InterestPaidNet
4443000
us-gaap Interest Paid Net
InterestPaidNet
3241000
bdsx Purchases Of Property Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
526000
bdsx Purchases Of Property Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
824000
bdsx Number Of Cancer Test
NumberOfCancerTest
5
bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company’s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating and money market accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of September 30, 2024 and December 31, 2023, see Note 9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> – Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36932000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33479000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8249000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5612000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28683000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2024Q3 us-gaap Depreciation
Depreciation
1000000
us-gaap Depreciation
Depreciation
2800000
CY2023Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
900000
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19017000
CY2024Q3 bdsx Intangible Asset Accumulated Amortization Excluding Goodwill
IntangibleAssetAccumulatedAmortizationExcludingGoodwill
12579000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6438000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18991000
CY2023Q4 bdsx Intangible Asset Accumulated Amortization Excluding Goodwill
IntangibleAssetAccumulatedAmortizationExcludingGoodwill
11080000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
501000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2000000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1979000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1021000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
73000
CY2024Q3 bdsx Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
747000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6321000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4958000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3855000
CY2024Q3 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
940000
CY2023Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
983000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2655000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2872000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8553000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3899000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4802000
CY2024Q3 us-gaap Notes Payable
NotesPayable
36141000
CY2023Q4 us-gaap Notes Payable
NotesPayable
35276000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
29000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
51000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
36112000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
13000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
21000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6000
CY2024Q3 bdsx Long Term Debt Maturities Repayments Of Principal In Year Three And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeAndThereafter
40000000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
40040000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3300000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
696000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3909000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3899000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4802000
CY2024Q3 us-gaap Notes Payable
NotesPayable
36141000
CY2023Q4 us-gaap Notes Payable
NotesPayable
35276000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
29000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
51000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
36112000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
13000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
21000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6000
CY2024Q3 bdsx Long Term Debt Maturities Repayments Of Principal In Year Three And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeAndThereafter
40000000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
40040000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3300000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y3M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
696000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3909000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4171000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4063000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4151000
CY2024Q3 bdsx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
28113000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
45103000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19288000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25815000
CY2024Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4171000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4063000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4151000
CY2024Q3 bdsx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
28113000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
45103000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19288000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25815000
CY2024Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharmaceutical Services and other).
CY2024Q3 us-gaap Revenues
Revenues
18151000
CY2023Q3 us-gaap Revenues
Revenues
13491000
us-gaap Revenues
Revenues
50894000
us-gaap Revenues
Revenues
34419000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
300000
bdsx Contract With Customer Liability Revenue Recognized Excluding Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance
500000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
700000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
809163
bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharmaceutical Services and other).
CY2024Q3 us-gaap Revenues
Revenues
18151000
CY2023Q3 us-gaap Revenues
Revenues
13491000
us-gaap Revenues
Revenues
50894000
us-gaap Revenues
Revenues
34419000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
300000
bdsx Contract With Customer Liability Revenue Recognized Excluding Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance
500000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
700000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
809163
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1515000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
954000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5373000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1515000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
954000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5373000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4292000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2041000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
964000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2226000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
221000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
27000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.72
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4019000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1250000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1719000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
822000
bdsx Description Of Offering Period Under Plan
DescriptionOfOfferingPeriodUnderPlan
ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
471843
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
175275
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4292000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2041000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
964000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2226000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
221000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
27000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.72
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4019000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1719000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
822000
bdsx Description Of Offering Period Under Plan
DescriptionOfOfferingPeriodUnderPlan
ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
471843
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
175275
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10949000
us-gaap Net Income Loss
NetIncomeLoss
-34680000
us-gaap Net Income Loss
NetIncomeLoss
-43007000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146296000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146296000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79709000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79709000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123634000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123634000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78672000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78672000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10949000
us-gaap Net Income Loss
NetIncomeLoss
-34680000
us-gaap Net Income Loss
NetIncomeLoss
-43007000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146296000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146296000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79709000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79709000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123634000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123634000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78672000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78672000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13801000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11651000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13801000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11651000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13801000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11651000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13801000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11651000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
bdsx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
bdsx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-119792-index-headers.html Edgar Link pending
0000950170-24-119792-index.html Edgar Link pending
0000950170-24-119792.txt Edgar Link pending
0000950170-24-119792-xbrl.zip Edgar Link pending
bdsx-20240930.htm Edgar Link pending
bdsx-20240930.xsd Edgar Link pending
bdsx-ex10_1.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bdsx-20240930_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending